<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="arts" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">arts</book-part-id>
      <title-group>
        <title>Arts Syndrome</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>de Brouwer</surname>
            <given-names>Arjan PM</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref ref-type="aff" rid="arts.Tc.aff1"/>
          <email>arjan.debrouwer@radboudumc.nl</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Duley</surname>
            <given-names>John A</given-names>
          </name>
          <degrees>PhD</degrees>
          <xref ref-type="aff" rid="arts.Tc.aff2"/>
          <email>john.duley@mater.org.au</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Christodoulou</surname>
            <given-names>John</given-names>
          </name>
          <degrees>MB BS, PhD</degrees>
          <xref ref-type="aff" rid="arts.Tc.aff3"/>
          <xref ref-type="aff" rid="arts.Tc.aff4"/>
          <email>johnc@chw.edu.au</email>
        </contrib>
      </contrib-group>
      <aff id="arts.Tc.aff1">Assistant Professor, Department of Human Genetics<break/>Radboud University Nijmegen Medical Center<break/>Nijmegen, The Netherlands</aff>
      <aff id="arts.Tc.aff2">University of Queensland<break/>Mater Hospital Pathology<break/>Brisbane, Australia</aff>
      <aff id="arts.Tc.aff3">Disciplines of Paediatrics and Child Health &#x00026; Genetic Medicine<break/>University of Sydney</aff>
      <aff id="arts.Tc.aff4">Western Sydney Genetics Program<break/>Children&#x02019;s Hospital at Westmead<break/>Sydney, Australia</aff>
      <pub-history>
        <date date-type="created">
          <day>21</day>
          <month>10</month>
          <year>2008</year>
        </date>
        <date date-type="updated">
          <day>18</day>
          <month>11</month>
          <year>2010</year>
        </date>
        <date date-type="revised">
          <day>29</day>
          <month>3</month>
          <year>2011</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="arterial-t" document-type="chapter">Arterial Tortuosity Syndrome</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="mld" document-type="chapter">Arylsulfatase A Deficiency</related-object>
      <abstract id="arts.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Arts syndrome, which is part of the spectrum of <italic toggle="yes">PRPS1</italic>-related disorders, is characterized by profound congenital sensorineural hearing impairment, early-onset hypotonia, delayed motor development, mild to moderate intellectual disability, ataxia, and increased risk of infection, all of which (with the exception of optic atrophy) present before age two years. Signs of peripheral neuropathy develop during early childhood. Twelve of 15 boys from the two Dutch families reported with Arts syndrome died before age six years of complications of infection. Carrier females can show late-onset (age &#x0003e;20 years) hearing impairment and other findings.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>Sequence analysis of <italic toggle="yes">PRPS1</italic>, the only gene associated with Arts syndrome, has detected pathogenic variants in both kindreds reported to date.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Educational program tailored to individual needs. Sensorineural hearing loss has been treated with cochlear implantation with good results. Ataxia and visual impairment from optic atrophy are treated in a routine manner.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Routine immunizations against common childhood infections and annual influenza immunization.</p>
          <p><italic toggle="yes">Surveillance:</italic> Regular neuropsychological, audiologic, and ophthalmologic examinations.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>Arts syndrome is inherited in an X-linked manner. If the mother is a carrier, the chance of transmitting the <italic toggle="yes">PRPS1</italic> pathogenic variant in each pregnancy is 50%. Males who inherit the pathogenic variant will be affected; females who inherit the pathogenic variant will be carriers and may or may not be mildly affected. Males with Arts syndrome do not reproduce. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the pathogenic variant in the family is known.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="arts.Diagnosis">
        <title>Diagnosis</title>
        <sec id="arts.Clinical_Diagnosis">
          <title>Clinical Diagnosis</title>
          <p>Arts syndrome, part of the spectrum of <italic toggle="yes">PRPS1</italic>-related disorders that includes <related-object link-type="booklink" source-id="gene" document-id="prs" document-type="chapter">PRS superactivity</related-object>, <related-object link-type="booklink" source-id="gene" document-id="cmtx5" document-type="chapter">X-linked Charcot-Marie-Tooth disease type 5</related-object> (CMTX5), and DFNX1 nonsyndromic hearing loss and deafness (DFN2) (see <xref ref-type="table" rid="arts.T.major_clinical_findings_in_prps1r">Table 2</xref>), is characterized by the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Intellectual disability</p>
            </list-item>
            <list-item>
              <p>Profound congenital sensorineural hearing impairment</p>
            </list-item>
            <list-item>
              <p>Early-onset hypotonia</p>
            </list-item>
            <list-item>
              <p>Delayed motor development</p>
            </list-item>
            <list-item>
              <p>Ataxia</p>
            </list-item>
            <list-item>
              <p>Optic atrophy</p>
            </list-item>
            <list-item>
              <p>Liability to infections, especially of the upper respiratory tract</p>
            </list-item>
          </list>
        </sec>
        <sec id="arts.Testing">
          <title>Testing</title>
          <p><bold>Serum concentration of uric acid.</bold> Although serum uric acid concentration in males with Arts syndrome tends to be low (0.13-0.16 mmol/L), it is still within the normal range (0.12-0.35 mmol/L) [<xref ref-type="bibr" rid="arts.REF.de_brouwer.2007.507">de Brouwer et al 2007</xref>].</p>
          <p>Note: (1) Serum uric acid concentration is not zero because PRS-II, which has the same enzyme activity as PRS-I, is active in tissues such as liver, which consequently will result in purine nucleotide synthesis and uric acid production. (2) However, a low/normal serum uric acid concentration may be helpful in ruling out a diagnosis of PRS superactivity, in which serum uric acid concentration is usually high.</p>
          <p><bold>Purine</bold>
<bold>analysis in urine</bold></p>
          <list list-type="bullet">
            <list-item>
              <p>Urine hypoxanthine is undetectable in Arts syndrome.</p>
            </list-item>
            <list-item>
              <p>When individuals with Arts syndrome are on a low purine diet, the uric acid to creatinine ratio in urine may also tend to be at the lower end of normal, but not zero.</p>
            </list-item>
            <list-item>
              <p>The concentrations of other purines in urine are within the normal range.</p>
            </list-item>
          </list>
          <p><bold>Phosphoribosylpyrophosphate synthetase (PRS) enzyme activity in erythrocytes and fibroblasts.</bold> In individuals with Arts syndrome, PRS enzyme activity is:</p>
          <list list-type="bullet">
            <list-item>
              <p>Completely absent in erythrocytes because PRS-I is the only isoform present [<xref ref-type="bibr" rid="arts.REF.de_brouwer.2007.507">de Brouwer et al 2007</xref>];</p>
            </list-item>
            <list-item>
              <p>Significantly lower in fibroblasts than in controls [<xref ref-type="bibr" rid="arts.REF.de_brouwer.2007.507">de Brouwer et al 2007</xref>].</p>
            </list-item>
          </list>
          <sec id="arts.Molecular_Genetic_Testing">
            <title>Molecular Genetic Testing</title>
            <p><bold>Gene.</bold>
<italic toggle="yes">PRPS1</italic>, encoding the enzyme phosphoribosyl pyrophosphate synthetase I, is the only gene known to be associated with Arts syndrome.</p>
            <p>
              <bold>Clinical testing</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Sequence analysis.</bold> Sequencing of the seven exons of the coding region of <italic toggle="yes">PRPS1</italic> in the two families known to have Arts syndrome identified a pathogenic missense variant in each [<xref ref-type="bibr" rid="arts.REF.de_brouwer.2007.507">de Brouwer et al 2007</xref>].</p>
              </list-item>
            </list>
            <table-wrap id="arts.T.summary_of_molecular_genetic_test" orientation="portrait" position="anchor">
              <label>Table 1. </label>
              <caption>
                <p>Summary of Molecular Genetic Testing Used in Arts Syndrome</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_arts.T.summary_of_molecular_genetic_test_1_1_1_1" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_arts.T.summary_of_molecular_genetic_test_1_1_1_1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_arts.T.summary_of_molecular_genetic_test_1_1_1_2" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_arts.T.summary_of_molecular_genetic_test_1_1_1_2">Test Method</th>
                    <th id="hd_h_arts.T.summary_of_molecular_genetic_test_1_1_1_3" rowspan="2" valign="middle" align="left" scope="col" colspan="1" headers="hd_h_arts.T.summary_of_molecular_genetic_test_1_1_1_3">Variants Detected&#x000a0;<sup>2</sup></th>
                    <th id="hd_h_arts.T.summary_of_molecular_genetic_test_1_1_1_4" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Variant Detection Frequency by Test Method&#x000a0;<sup>3</sup></th>
                  </tr>
                  <tr>
                    <th headers="hd_h_arts.T.summary_of_molecular_genetic_test_1_1_1_4" id="hd_h_arts.T.summary_of_molecular_genetic_test_1_1_2_1" valign="middle" colspan="1" align="left" scope="colgroup" rowspan="1">Affected Males</th>
                    <th headers="hd_h_arts.T.summary_of_molecular_genetic_test_1_1_1_4" id="hd_h_arts.T.summary_of_molecular_genetic_test_1_1_2_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Carrier Females</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_arts.T.summary_of_molecular_genetic_test_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                      <italic toggle="yes">PRPS1</italic>
                    </td>
                    <td headers="hd_h_arts.T.summary_of_molecular_genetic_test_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>4</sup></td>
                    <td headers="hd_h_arts.T.summary_of_molecular_genetic_test_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Single-nucleotide variants</td>
                    <td headers="hd_h_arts.T.summary_of_molecular_genetic_test_1_1_1_4 hd_h_arts.T.summary_of_molecular_genetic_test_1_1_2_1" valign="middle" align="left" rowspan="1" colspan="1">100%&#x000a0;<sup>5</sup></td>
                    <td headers="hd_h_arts.T.summary_of_molecular_genetic_test_1_1_1_4 hd_h_arts.T.summary_of_molecular_genetic_test_1_1_2_2" valign="middle" align="left" rowspan="1" colspan="1">100%&#x000a0;<sup>4</sup></td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="arts.TF.1.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="arts" object-id="arts.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
                </fn>
                <fn id="arts.TF.1.2">
                  <label>2. </label>
                  <p>See <xref ref-type="sec" rid="arts.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants.</p>
                </fn>
                <fn id="arts.TF.1.3">
                  <label>3. </label>
                  <p>The ability of the test method used to detect a variant that is present in the indicated gene</p>
                </fn>
                <fn id="arts.TF.1.4">
                  <label>4. </label>
                  <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="arts.TF.1.5">
                  <label>5. </label>
                  <p>Two families reported to date [<xref ref-type="bibr" rid="arts.REF.de_brouwer.2007.507">de Brouwer et al 2007</xref>]</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p><bold>Interpretation of test results.</bold> To determine if a missense variant is pathogenic, it may be necessary to look for biochemical evidence of Arts syndrome by measuring the serum concentration of uric acid and purines in the urine.</p>
          </sec>
        </sec>
        <sec id="arts.Testing_Strategy">
          <title>Testing Strategy</title>
          <p>
            <bold>To establish the diagnosis in a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>
                <bold>Suggestive findings</bold>
              </p>
              <list list-type="bullet">
                <list-item>
                  <p>Serum uric acid concentration lower than average</p>
                </list-item>
                <list-item>
                  <p>Absent/low hypoxanthine on analysis of purines in the urine</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>
                <bold>Definitive diagnosis</bold>
              </p>
              <list list-type="bullet">
                <list-item>
                  <p>Identification of a pathogenic variant on sequence analysis of <italic toggle="yes">PRPS1</italic></p>
                </list-item>
                <list-item>
                  <p>Absence of PRS enzyme activity in erythrocytes</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p><bold>Carrier testing for at-risk relatives</bold> requires prior identification of the pathogenic variant in the family.</p>
          <p>Note: (1) Carriers are heterozygotes for this X-linked disorder and may develop clinical findings related to the disorder, most notably late-onset (age &#x0003e;20 years) hearing impairment. (2) Identification of female carriers requires either (a) prior identification of the pathogenic variant in the family or (b) molecular genetic testing by sequence analysis if an affected male is not available for testing.</p>
          <p><bold>Prenatal diagnosis and preimplantation genetic diagnosis (PGD)</bold> for at-risk pregnancies require prior identification of the pathogenic variant in the family.</p>
        </sec>
      </sec>
      <sec id="arts.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="arts.Clinical_Description">
          <title>Clinical Description</title>
          <p>Arts syndrome is characterized by intellectual disability, early-onset hypotonia, ataxia, delayed motor development, profound congenital sensorineural hearing impairment, and progressive optic atrophy [<xref ref-type="bibr" rid="arts.REF.arts.1993.535">Arts et al 1993</xref>, <xref ref-type="bibr" rid="arts.REF.de_brouwer.2007.507">de Brouwer et al 2007</xref>].</p>
          <p>At birth these symptoms can be present in various combinations. All symptoms except for the visual impairment become apparent in the first two years of life. Visual impairment usually becomes obvious after age two years.</p>
          <p>Delayed motor nerve conduction velocities and an electromyography suggestive of denervation develop during early childhood and are consistent with clinical findings that suggest peripheral neuropathy.</p>
          <p>Affected males usually have mild to moderate intellectual disability; however, cognitive abilities can be difficult to assess in the presence of combined visual and hearing impairment.</p>
          <p>Liability to infections, especially upper-respiratory tract infections, resulted in death before age six years in 12 of 15 boys from the two Dutch families reported with Arts syndrome. During infection, the slowly progressive muscle weakness is punctuated by acute deterioration in muscle strength, which may result in respiratory failure requiring mechanical ventilation.</p>
          <p><bold>Carrier females</bold> can show isolated and/or milder manifestations, most notably late-onset (&#x0003e; age 20 years) hearing impairment; however, ataxia, hypotonia, and hyperreflexia have been reported as well [<xref ref-type="bibr" rid="arts.REF.arts.1993.535">Arts et al 1993</xref>].</p>
          <p>
            <bold>Other</bold>
          </p>
          <p><bold>MRI</bold> shows no recognizable abnormalities, such as reduction of white matter in the brain, which would be indicative of demyelination [<xref ref-type="bibr" rid="arts.REF.de_brouwer.2007.507">de Brouwer et al 2007</xref>].</p>
          <p><bold>Sural nerve biopsy</bold> in a five-year-old boy with Arts syndrome from the original Dutch family showed a loss of myelinated fibers, but no signs of demyelination or axonal degeneration [<xref ref-type="bibr" rid="arts.REF.arts.1993.535">Arts et al 1993</xref>]. Sural nerve biopsy of a two-year-old boy from the Australian family, who had absent lower-limb deep tendon reflexes and nerve conduction studies indicative of peripheral neuropathy, showed mild paranodal demyelination indicative of peripheral neuropathy [<xref ref-type="bibr" rid="arts.REF.de_brouwer.2007.507">de Brouwer et al 2007</xref>].</p>
          <p><bold>Autopsy</bold> of one individual who died at age five and a half years revealed complete absence of myelinated axons in the posterior columns of the spinal cord, although their number and appearance were normal in the other tracts [<xref ref-type="bibr" rid="arts.REF.arts.1993.535">Arts et al 1993</xref>]. A number of dorsal root nerves showed the same abnormalities as posterior columns. No abnormalities were seen in the brain stem or in the gray and white matter of the cerebral and cerebellar hemispheres.</p>
        </sec>
        <sec id="arts.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>Computer-assisted molecular modeling showed that pathogenic variants causing Arts syndrome and <related-object link-type="booklink" source-id="gene" document-id="cmtx5" document-type="chapter">CMTX5</related-object> disturb the ATP binding site of PRS-I.</p>
          <p>Pathogenic variants that result in <related-object link-type="booklink" source-id="gene" document-id="prs" document-type="chapter">PRS superactivity</related-object> disturb either one or both allosteric sites that are involved in the inhibition of PRS I enzyme activity.</p>
          <p>Pathogenic variants that lead to DFNX1 nonsyndromic hearing loss and deafness (DFN2) either disturb local stability of PRS I or moderately affect interactions in the trimer interface.</p>
        </sec>
        <sec id="arts.Penetrance">
          <title>Penetrance</title>
          <p>Penetrance in males is complete.</p>
        </sec>
        <sec id="arts.Prevalence">
          <title>Prevalence</title>
          <p>Two kindreds with Arts syndrome have been identified worldwide [<xref ref-type="bibr" rid="arts.REF.de_brouwer.2007.507">de Brouwer et al 2007</xref>].</p>
        </sec>
      </sec>
      <sec id="arts.Genetically_Related_Allelic_Disorde">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>The spectrum of <italic toggle="yes">PRPS1</italic>-related disorders includes four phenotypes &#x02013; <related-object link-type="booklink" source-id="gene" document-id="prs" document-type="chapter">PRS superactivity</related-object>, <related-object link-type="booklink" source-id="gene" document-id="cmtx5" document-type="chapter">CMTX5</related-object>, <related-object link-type="booklink" source-id="gene" document-id="dfnx1" document-type="chapter">DFNX1 nonsyndromic hearing loss and deafness</related-object> (DFN2), and Arts syndrome &#x02013; previously thought to be distinct entities (<xref ref-type="table" rid="arts.T.major_clinical_findings_in_prps1r">Table 2</xref>).</p>
        <table-wrap id="arts.T.major_clinical_findings_in_prps1r" orientation="portrait" position="anchor">
          <label>Table 2. </label>
          <caption>
            <p>Major Clinical Findings in <italic toggle="yes">PRPS1</italic>-Related Disorders by Phenotype</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_arts.T.major_clinical_findings_in_prps1r_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Phenotype</th>
                <th id="hd_h_arts.T.major_clinical_findings_in_prps1r_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gouty Arthritis&#x000a0;<sup>1</sup></th>
                <th id="hd_h_arts.T.major_clinical_findings_in_prps1r_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Peripheral Neuropathy</th>
                <th id="hd_h_arts.T.major_clinical_findings_in_prps1r_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Intellectual Disability</th>
                <th id="hd_h_arts.T.major_clinical_findings_in_prps1r_1_1_1_5" valign="middle" align="left" scope="col" rowspan="1" colspan="1">SNHL</th>
                <th id="hd_h_arts.T.major_clinical_findings_in_prps1r_1_1_1_6" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Other</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_arts.T.major_clinical_findings_in_prps1r_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">PRS superactivity, infantile onset</td>
                <td headers="hd_h_arts.T.major_clinical_findings_in_prps1r_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">+</td>
                <td headers="hd_h_arts.T.major_clinical_findings_in_prps1r_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x02013;</td>
                <td headers="hd_h_arts.T.major_clinical_findings_in_prps1r_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">+</td>
                <td headers="hd_h_arts.T.major_clinical_findings_in_prps1r_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">+</td>
                <td headers="hd_h_arts.T.major_clinical_findings_in_prps1r_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">Hypotonia, ataxia</td>
              </tr>
              <tr>
                <td headers="hd_h_arts.T.major_clinical_findings_in_prps1r_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">PRS superactivity, late juvenile/early adult onset</td>
                <td headers="hd_h_arts.T.major_clinical_findings_in_prps1r_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">+</td>
                <td headers="hd_h_arts.T.major_clinical_findings_in_prps1r_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x02013;</td>
                <td headers="hd_h_arts.T.major_clinical_findings_in_prps1r_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">&#x02013;</td>
                <td headers="hd_h_arts.T.major_clinical_findings_in_prps1r_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">&#x02013;</td>
                <td headers="hd_h_arts.T.major_clinical_findings_in_prps1r_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">&#x02013;</td>
              </tr>
              <tr>
                <td headers="hd_h_arts.T.major_clinical_findings_in_prps1r_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">CMTX5</td>
                <td headers="hd_h_arts.T.major_clinical_findings_in_prps1r_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">&#x02013;</td>
                <td headers="hd_h_arts.T.major_clinical_findings_in_prps1r_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">+</td>
                <td headers="hd_h_arts.T.major_clinical_findings_in_prps1r_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">&#x02013;</td>
                <td headers="hd_h_arts.T.major_clinical_findings_in_prps1r_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Early onset</td>
                <td headers="hd_h_arts.T.major_clinical_findings_in_prps1r_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">Optic neuropathy</td>
              </tr>
              <tr>
                <td headers="hd_h_arts.T.major_clinical_findings_in_prps1r_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">DFNX1 nonsyndromic hearing loss and deafness (DFN2)</td>
                <td headers="hd_h_arts.T.major_clinical_findings_in_prps1r_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">&#x02013;</td>
                <td headers="hd_h_arts.T.major_clinical_findings_in_prps1r_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x02013;</td>
                <td headers="hd_h_arts.T.major_clinical_findings_in_prps1r_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">&#x02013;</td>
                <td headers="hd_h_arts.T.major_clinical_findings_in_prps1r_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Profound postlingual/congenital</td>
                <td headers="hd_h_arts.T.major_clinical_findings_in_prps1r_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">&#x02013;</td>
              </tr>
              <tr>
                <td headers="hd_h_arts.T.major_clinical_findings_in_prps1r_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Arts syndrome</td>
                <td headers="hd_h_arts.T.major_clinical_findings_in_prps1r_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">&#x02013;</td>
                <td headers="hd_h_arts.T.major_clinical_findings_in_prps1r_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">+</td>
                <td headers="hd_h_arts.T.major_clinical_findings_in_prps1r_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">+</td>
                <td headers="hd_h_arts.T.major_clinical_findings_in_prps1r_1_1_1_5" valign="middle" align="left" rowspan="1" colspan="1">Profound congenital</td>
                <td headers="hd_h_arts.T.major_clinical_findings_in_prps1r_1_1_1_6" valign="middle" align="left" rowspan="1" colspan="1">Hypotonia, ataxia, optic atrophy, risk for infection</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>SNHL= sensorineural hearing loss</p>
            </fn>
            <fn id="arts.TF.2.1">
              <label>1. </label>
              <p>Associated with hyperuricemia, hyperuricosuria</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><related-object link-type="booklink" source-id="gene" document-id="prs" document-type="chapter"><bold>PRS superactivity</bold></related-object><bold>.</bold> The PRS superactivity phenotype can be divided into a severe and a mild phenotype.</p>
        <p>The severe phenotype is characterized by infantile or early-childhood-onset hyperuricemia and hyperuricosuria, which results in gouty arthritis that is usually accompanied by a variable combination of intellectual disability, sensorineural hearing loss, hypotonia, and ataxia. Carrier females in families with the severe form of PRS superactivity can also show one or more of these features [<xref ref-type="bibr" rid="arts.REF.garc_apav_a.2003.2036">Garc&#x000ed;a-Pav&#x000ed;a et al 2003</xref>].</p>
        <p>The milder phenotype is characterized by late-juvenile- or early-adult-onset hyperuricemia and hyperuricosuria. Obvious neurologic findings are not present.</p>
        <p><related-object link-type="booklink" source-id="gene" document-id="cmtx5" document-type="chapter"><bold>CMTX5</bold></related-object><bold>.</bold> CMTX5 is characterized by peripheral neuropathy, early-onset sensorineural hearing impairment, and progressive optic neuropathy starting between ages eight and 13 years [<xref ref-type="bibr" rid="arts.REF.rosenberg.1967.827">Rosenberg &#x00026; Chutorian 1967</xref>, <xref ref-type="bibr" rid="arts.REF.kim.2007.552">Kim et al 2007</xref>]. Progressive hypotonia, gait disturbances, and loss of deep-tendon reflexes with an onset between ages ten and 12 years have also been reported. Affected individuals have normal intellect. Carrier females do not have symptoms of CMTX5.</p>
        <p><related-object link-type="booklink" source-id="gene" document-id="dfnx1" document-type="chapter"><bold>DFN2.</bold></related-object> Individuals with DFNX1 nonsyndromic hearing loss and deafness (DFN2) have postlingual progressive nonsyndromic hearing loss, although in one family congenital profound nonsyndromic hearing loss was reported [<xref ref-type="bibr" rid="arts.REF.lui.2009.65">Lui et al 2009</xref>]. Affected individuals have normal intellect. Carrier females do not manifest symptoms.</p>
      </sec>
      <sec id="arts.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Arts syndrome can be distinguished clinically from <related-object link-type="booklink" source-id="gene" document-id="prs" document-type="chapter">PRS superactivity</related-object> by the presence of gouty arthritis in the latter. In Arts syndrome purine production is low/normal, whereas in PRS superactivity purine overproduction is a primary manifestation. Because dietary purine contributes significantly to urinary uric acid, a standard low purine diet is required for the biochemical diagnosis of purine over- or underproduction.</p>
        <p>Arts syndrome can be distinguished clinically from <related-object link-type="booklink" source-id="gene" document-id="cmtx5" document-type="chapter">CMTX5</related-object> because CMTX5 does not have intellectual disability or recurrent infections. Arts syndrome and CMTX5 cannot be distinguished using results of serum uric acid testing.</p>
        <p>Arts syndrome can be distinguished clinically from DFNX1 nonsyndromic hearing loss and deafness (DFN2) because individuals with DNF2 do not have intellectual disability or recurrent infections. Arts syndrome and DFN2 cannot be distinguished using biochemical testing.</p>
        <p>Other disorders similar to Arts syndrome have not been described, except perhaps for spinocerebellar ataxia, X-linked 3, although the features and progression in this disorder seem to be somewhat different [<xref ref-type="bibr" rid="arts.REF.schmidley.1987.1344">Schmidley et al 1987</xref>]. Moreover, this disorder has not been assigned to a specific region on the X chromosome; thus, it remains to be seen whether it may be caused by <italic toggle="yes">PRPS1</italic> pathogenic variants as well.</p>
      </sec>
      <sec id="arts.Management">
        <title>Management</title>
        <sec id="arts.Evaluations_Following_Initial_Diagn">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease in an individual diagnosed with Arts syndrome, the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Neurologic evaluation for manifestations of hypotonia, ataxia, presence/absence of tendon reflexes</p>
            </list-item>
            <list-item>
              <p>Audiometry for evidence of hearing loss</p>
            </list-item>
            <list-item>
              <p>Eye examination for evidence of optic atrophy</p>
            </list-item>
            <list-item>
              <p>Assessment of intellectual abilities</p>
            </list-item>
            <list-item>
              <p>Analysis of the family pedigree for other possible affected individuals and carrier females</p>
            </list-item>
          </list>
        </sec>
        <sec id="arts.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p><bold>Intellectual disability.</bold> An individualized educational support program tailored to the patient&#x02019;s needs and based on assessment of cognitive abilities should be provided.</p>
          <p><bold>Sensorineural hearing loss</bold>. See <related-object link-type="booklink" source-id="gene" document-id="deafness-overview" document-type="chapter">Deafness and Hereditary Hearing Loss Overview</related-object>, Management. Cochlear implantation in the two affected Australian males was associated with improved communication skills.</p>
          <p><bold>Optic atrophy</bold>. No treatment is available.</p>
          <p><bold>Ataxia</bold>. See <related-object link-type="booklink" source-id="gene" document-id="ataxias" document-type="chapter">Hereditary Ataxias</related-object>, Management.</p>
        </sec>
        <sec id="arts.Prevention_of_Secondary_Complicatio">
          <title>Prevention of Secondary Complications</title>
          <p>Because of immune system compromise in males with Arts syndrome, the following are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>An annual influenza immunization</p>
            </list-item>
            <list-item>
              <p>Routine immunizations against other common childhood infections (e.g. measles, mumps)</p>
            </list-item>
          </list>
        </sec>
        <sec id="arts.Surveillance">
          <title>Surveillance</title>
          <p>Cognitive impairment appears to be non-progressive, but repeat neuropsychologic assessments are recommended to help guide educational support programs.</p>
          <p>Although the sensorineural deafness appears to be static (albeit very severe), regular audiologic assessment is recommended so that educational support can be optimized.</p>
          <p>Visual impairment appears to be progressive; thus, regular evaluation by an ophthalmologist is recommended.</p>
        </sec>
        <sec id="arts.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>Females at risk of being carriers should be evaluated for the family-specific <italic toggle="yes">PRPS1</italic> pathogenic variant because clinical manifestations observed in carriers may only become apparent at a later age.</p>
          <p>See <xref ref-type="sec" rid="arts.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="arts.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Dietary <italic toggle="yes">S</italic>-adenosylmethionine (SAM) supplementation could theoretically alleviate some of the symptoms of Arts syndrome by providing an oral source purine nucleotide precursor that is not PRPP dependent. Furthermore, SAM is known to cross the blood-brain barrier. An adult with HPRT deficiency has been reported to benefit neurologically from SAM administration without untoward side effects [<xref ref-type="bibr" rid="arts.REF.glick.2006.687">Glick 2006</xref>].</p>
          <p>An open-label clinical trial of SAM in two Australian brothers (ages 14 and 13 in 2010) with Arts syndrome is continuing [J Christodoulou et al, unpublished data; approved by the ethics and drug committees, Children's Hospital at Westmead, Sydney, Australia]. Oral SAM supplementation is presently set at 30 mg/kg/day. The brothers appear to have had significant benefit from this therapy based on decreased number of hospitalizations and stabilization of nocturnal BIPAP requirements; however, slight deterioration in their vision has been noted.</p>
          <p>Mildly affected carrier females from families with Arts syndrome may also benefit from SAM supplementation in their diet, although this remains to be tested.</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="arts.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="arts.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Arts syndrome is inherited in an X-linked manner.</p>
        </sec>
        <sec id="arts.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a male proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>In a family with more than one affected individual, the mother of an affected male is likely to be an obligate carrier.</p>
              <list list-type="bullet">
                <list-item>
                  <p>A mother who is a carrier may have a <italic toggle="yes">de novo</italic> pathogenic variant or she may have inherited the pathogenic variant from one of her parents.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>The father of an affected male will have neither the disease nor the pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>When an affected male is the only affected individual in the family several possibilities regarding his mother's carrier status need to be considered:</p>
              <list list-type="bullet">
                <list-item>
                  <p>He has a <italic toggle="yes">de novo</italic> pathogenic variant in <italic toggle="yes">PRPS1</italic> and his mother is not a carrier. The frequency of <italic toggle="yes">de novo</italic> pathogenic variants is not known.</p>
                </list-item>
                <list-item>
                  <p>His mother has a <italic toggle="yes">de novo</italic> pathogenic variant in <italic toggle="yes">PRPS1</italic>, either as (a) a "germline variant" (i.e., present at the time of her conception and therefore in every cell of her body); or (b) "germline mosaicism" (i.e., present in some of her germ cells only).</p>
                </list-item>
                <list-item>
                  <p>His mother has a pathogenic variant that she inherited from a maternal female ancestor.</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p>
            <bold>Parents of a female proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>If the proband is a female and if pedigree analysis reveals that she is the only affected family member, it is reasonable to offer molecular genetic testing to both of her parents to determine risks to family members.</p>
            </list-item>
            <list-item>
              <p>If the proband's father is asymptomatic, it is possible, but not likely, that he has the pathogenic variant in some cells in his body (somatic or germline mosaicism). If her father is asymptomatic and does not have somatic or germline mosaicism for the altered gene, the possible genetic explanations for the origin of the proband's pathogenic variant are the same as for a male proband with a negative family history.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of the proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to the sibs of a proband depends on the genetic status of the parents.</p>
              <list list-type="bullet">
                <list-item>
                  <p>If the mother has a <italic toggle="yes">PRPS1</italic> pathogenic variant, the chance of transmitting the variant in each pregnancy is 50%. Male sibs who inherit the pathogenic variant will be affected; female sibs who inherit the pathogenic variant will be carriers and may or may not be mildly affected.</p>
                </list-item>
                <list-item>
                  <p>If the father of a female proband is affected, all female sibs will inherit the pathogenic variant and may or may not be mildly affected. None of the male sibs will inherit the pathogenic variant.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>When the parents are clinically unaffected, the risk to the sibs of a proband appears to be low but greater than that of the general population.</p>
              <list list-type="bullet">
                <list-item>
                  <p>If the pathogenic variant cannot be detected in the DNA of either parent of the proband, two possible explanations are germline mosaicism in a parent or a <italic toggle="yes">de novo</italic> pathogenic variant in the proband.</p>
                </list-item>
                <list-item>
                  <p>Although no instances of germline mosaicism have been reported, it remains a possibility.</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p><bold>Offspring of a male proband.</bold> Males with Arts syndrome do not reproduce.</p>
          <p><bold>Offspring of a female proband.</bold> Females with a <italic toggle="yes">PRPS1</italic> pathogenic variant have a 50% chance of transmitting the gene to each child; sons who inherit the gene will be affected; daughters have a range of possible phenotypic expression.</p>
          <p><bold>Other family members of the proband.</bold> If a parent of the proband also has a pathogenic variant, his or her female family members may be at risk of being carriers (asymptomatic or symptomatic) and his or her male family members may be at risk of being affected depending on their gender and genetic relationship to the proband.</p>
        </sec>
        <sec id="arts.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carrier testing is possible if the pathogenic variant has been identified in the family.</p>
        </sec>
        <sec id="arts.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="arts.Prenatal_Testing_and_Preimplantatio">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">PRPS1</italic> pathogenic variant has been identified in an affected family member, prenatal diagnosis for a pregnancy at increased risk and preimplantation genetic diagnosis for Arts syndrome are possible.</p>
        </sec>
      </sec>
      <sec id="arts.Resources">
        <title>Resources</title>
      </sec>
      <sec id="arts.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">PRPS1</italic> consists of seven exons that code for PRS-I, a protein of 318 amino acid residues. Only one isoform has been described for PRS-I. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="arts" object-id="arts.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Pathogenic variants.</bold> To date, only two pathogenic variants have been identified (see <xref ref-type="table" rid="arts.T.selected_prps1_variants">Table 3</xref>), resulting in missense changes at the protein level.</p>
        <table-wrap id="arts.T.selected_prps1_variants" orientation="portrait" position="anchor">
          <label>Table 3. </label>
          <caption>
            <p>Selected <italic toggle="yes">PRPS1</italic> Variants</p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_arts.T.selected_prps1_variants_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variant Classification</th>
                <th id="hd_h_arts.T.selected_prps1_variants_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                <th id="hd_h_arts.T.selected_prps1_variants_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change <break/>(Alias&#x000a0;<sup>1</sup>)</th>
                <th id="hd_h_arts.T.selected_prps1_variants_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_arts.T.selected_prps1_variants_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                  <bold>Benign</bold>
                </td>
                <td headers="hd_h_arts.T.selected_prps1_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.336T&#x0003e;C</td>
                <td headers="hd_h_arts.T.selected_prps1_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.(=)&#x000a0;<sup>2</sup><break/>(Val112Val)</td>
                <td headers="hd_h_arts.T.selected_prps1_variants_1_1_1_4" rowspan="3" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&#x00026;id=164663865">NM_002764.3</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&#x00026;id=4506127">NP_002755.1</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_arts.T.selected_prps1_variants_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                  <bold>Pathogenic</bold>
                </td>
                <td headers="hd_h_arts.T.selected_prps1_variants_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.398A&#x0003e;C</td>
                <td headers="hd_h_arts.T.selected_prps1_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Gln133Pro</td>
              </tr>
              <tr>
                <td headers="hd_h_arts.T.selected_prps1_variants_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.455T&#x0003e;C</td>
                <td headers="hd_h_arts.T.selected_prps1_variants_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Leu152Pro</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
            <fn id="arts.TF.3.1">
              <label>1. </label>
              <p>Variant designation that does not conform to current naming conventions</p>
            </fn>
            <fn id="arts.TF.3.2">
              <label>2. </label>
              <p>p.(=) designates that protein has not been analyzed, but no change is expected.</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold> PRS-I catalyzes the synthesis of phosphoribosyl pyrophosphate (PRPP) from ATP and ribose-5-phosphate. PRPP is essential for the <italic toggle="yes">de novo</italic> synthesis of purine, pyrimidine, and pyridine nucleotides. For purine synthesis, PRPP is utilized as a substrate for PRPP amidotransferase, which is the first step in the <italic toggle="yes">de novo</italic> purine synthesis pathway, producing purine nucleotides such as ATP and GTP, and serves specifically as the rate-limiting reaction for purine nucleotide synthesis in vivo. PRPP is also essential for pyrimidine nucleotide synthesis, where it acts as cofactor for uridine monophosphate synthetase, which converts orotic acid into UMP, the precursor of other pyrimidine nucleotides including UTP, CTP, and TTP. Finally, PRPP is utilized for pyridine nucleotide synthesis by nicotinate phosphoribosyl transferase and nicotinamide phosphoribosyl transferase, which add a ribonucleotide moiety to nicotinic acid and nicotinamide respectively, which in turn are converted into the important cofactor NAD.</p>
        <p>Apart from <italic toggle="yes">de novo</italic> synthesis of purine, pyrimidine, and pyridine nucleotides, PRPP is also essential for the salvage of purine bases by hypoxanthine guanine phosphoribosyl transferase and adenine phosphoribosyl transferase. This mechanism ensures efficient reutilization of purine bases and nucleosides, since <italic toggle="yes">de novo</italic> purine nucleotide synthesis using PRPP as the substrate requires in total of seven moles of ATP for generation of each mole of nucleotide, whereas salvage requires only one mole of ATP, for the synthesis of PRPP.</p>
        <p><bold>Abnormal gene product.</bold>
<italic toggle="yes">In silico</italic> molecular modeling predicted that both missense variants would result in a loss of PRS-I activity, which was accordingly demonstrated by in vitro PRS enzyme assays in erythrocytes and fibroblasts from the Australian family and fibroblasts from the Dutch kindred. This was reflected by undetectable urine hypoxanthine and reduced plasma uric acid levels in the two patients from the Australian family.</p>
      </sec>
      <sec id="arts.References">
        <title>References</title>
        <sec id="arts.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="arts.Literature_Cited.reflist0">
            <ref id="arts.REF.arts.1993.535">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Arts</surname>
                    <given-names>WF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loonen</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sengers</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Slooff</surname>
                    <given-names>JL</given-names>
                  </name>
                </person-group>
                <year>1993</year>
                <article-title>X-linked ataxia, weakness, deafness, and loss of vision in early childhood with a fatal course.</article-title>
                <source>Ann Neurol</source>
                <volume>33</volume>
                <fpage>535</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">8498830</pub-id>
              </element-citation>
            </ref>
            <ref id="arts.REF.de_brouwer.2007.507">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>de Brouwer</surname>
                    <given-names>AP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>KL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duley</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Kuilenburg</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nabuurs</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Egmont-Petersen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lugtenberg</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zoetekouw</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Banning</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roeffen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hamel</surname>
                    <given-names>BC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weaving</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ouvrier</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donald</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wevers</surname>
                    <given-names>RA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Christodoulou</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Bokhoven</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Arts syndrome is caused by loss-of-function mutations in PRPS1.</article-title>
                <source>Am J Hum Genet</source>
                <volume>81</volume>
                <fpage>507</fpage>
                <lpage>18</lpage>
                <pub-id pub-id-type="pmid">17701896</pub-id>
              </element-citation>
            </ref>
            <ref id="arts.REF.garc_apav_a.2003.2036">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Garc&#x000ed;a-Pav&#x000ed;a</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Torres</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rivero</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ahmed</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garcia-Puig</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Becker</surname>
                    <given-names>MA</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Phosphoribosylpyrophosphate synthetase overactivity as a cause of uric acid overproduction in a young woman.</article-title>
                <source>Arthritis Rheum</source>
                <volume>48</volume>
                <fpage>2036</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">12847698</pub-id>
              </element-citation>
            </ref>
            <ref id="arts.REF.glick.2006.687">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Glick</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Dramatic reduction in self-injury in Lesch-Nyhan disease following S-adenosylmethionine administration.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>29</volume>
                <fpage>687</fpage>
                <pub-id pub-id-type="pmid">16906475</pub-id>
              </element-citation>
            </ref>
            <ref id="arts.REF.kim.2007.552">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sohn</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shy</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krajewski</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hwang</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Park</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jang</surname>
                    <given-names>SY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Won</surname>
                    <given-names>HH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Choi</surname>
                    <given-names>BO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hong</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suh</surname>
                    <given-names>YL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ki</surname>
                    <given-names>CS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>SY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>JW</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Mutations in PRPS1, which encodes the phosphoribosyl pyrophosphate synthetase enzyme critical for nucleotide biosynthesis, cause hereditary peripheral neuropathy with hearing loss and optic neuropathy (cmtx5).</article-title>
                <source>Am J Hum Genet</source>
                <volume>81</volume>
                <fpage>552</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">17701900</pub-id>
              </element-citation>
            </ref>
            <ref id="arts.REF.lui.2009.65">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lui</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Han</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Han</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ouyang</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cheng</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jin</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bitner-Glindzicz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kong</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xu</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kantardzhieva</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eavey</surname>
                    <given-names>RD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seidman</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seidman</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Du</surname>
                    <given-names>LL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>ZY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dai</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Teng</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yan</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yuan</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>loss-of-function mutations in the PRPS1 gene cause non-syndromic X-linked sensorineural deafness (DFN2).</article-title>
                <source>Am J Hum Genet</source>
                <volume>86</volume>
                <fpage>65</fpage>
                <lpage>71</lpage>
              </element-citation>
            </ref>
            <ref id="arts.REF.rosenberg.1967.827">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rosenberg</surname>
                    <given-names>RN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chutorian</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>1967</year>
                <article-title>Familial opticoacoustic nerve degeneration and polyneuropathy.</article-title>
                <source>Neurology</source>
                <volume>17</volume>
                <fpage>827</fpage>
                <lpage>32</lpage>
                <pub-id pub-id-type="pmid">6069085</pub-id>
              </element-citation>
            </ref>
            <ref id="arts.REF.schmidley.1987.1344">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Schmidley</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levinsohn</surname>
                    <given-names>MW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manetto</surname>
                    <given-names>V</given-names>
                  </name>
                </person-group>
                <year>1987</year>
                <article-title>Infantile X-linked ataxia and deafness: a new clinicopathologic entity.</article-title>
                <source>Neurology</source>
                <volume>37</volume>
                <fpage>1344</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">3614654</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="arts.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="arts.Suggested_Reading.reflist0">
            <ref id="arts.REF.dalbeth.2013">
              <mixed-citation publication-type="book">Dalbeth N, Merriman T. Hyperuricemia and gout. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio AB, eds. <italic toggle="yes">The Online Metabolic and Molecular Bases of Inherited Disease (OMMBID)</italic>. Chap 106. New York: McGraw-Hill. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ommbid.mhmedical.com/">online</ext-link>. 2013.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="arts.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="arts.Acknowledgments">
          <title>Acknowledgments</title>
          <p>The authors are grateful to the families of the Dutch and Australian patients for providing samples used for biochemical and molecular analyses over a number of years.</p>
        </sec>
        <sec id="arts.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>29 March 2011 (cd) Revision: edits to Differential Diagnosis</p>
            </list-item>
            <list-item>
              <p>4 January 2011 (cd) Revision: changes to therapies under investigation</p>
            </list-item>
            <list-item>
              <p>18 November 2010 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>21 October 2008 (me) Review posted live</p>
            </list-item>
            <list-item>
              <p>3 June 2008 (apmb) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
